Data continue to accrue on the use of biosimilar infliximab, CT-P13 (Inflectra, Remsima), in a variety of disease states, and a recent study among patients with ankylosing spondylitis (AS) who were treated with the biosimilar demonstrated infrequent discontinuation of therapy.
Data continue to accrue on the use of biosimilar infliximab, CT-P13 (Inflectra, Remsima), in a variety of disease states, and a recent study among patients with ankylosing spondylitis (AS) who were treated with the biosimilar demonstrated infrequent discontinuation of therapy.
The study relied on the Korean College of Rheumatology biologics registry, or KOBIO, a prospective, observational registry that gathers data on patients with inflammatory diseases who are treated with biologics. Researchers assessed data from 224 patients with AS who were treated with CT-P13 and enrolled in the registry between 2012 and 2017. In total, 83.2% of these patients received the biosimilar as a first-line therapy.
Overall, disease activity decreased markedly from baseline and remained stable during follow-up. In total, 56.5% and 82.2% of patients had major or clinically important improvement, respectively, as measured by Ankylosing Spondylitis Disease Activity Score.
Data on retention were available for 208 of the patients (173 of whom were receiving the biosimilar as a first-line treatment). Overall retention at 4 years was 66%. The overall median duration of CT-P13 treatment was 2.05 years (range, 0.04-4.18). The median treatment duration in patients receiving first-line treatment was 2.09 years (range, 0.04-4.18), versus 1.11 years (range, 0.04-4.01) in patients for whom the biosimilar was a subsequent line of therapy.
Overall, 15.6% of patients switched from CT-P13 to a different therapy (most frequently to golimumab or adalimumab), and 13.1% discontinued all biologic treatment. Lack of efficacy was cited by 13.9% of patients as a reason for a change to treatment, while a total of 5 patients, all of whom were receiving first-line CT-P13, cited clinical remission as a reason for discontinuation.
Overall, 48.4% of patients reported 313 adverse events (AEs). In total, 72 of these AEs were considered to be related to CT-P13 treatment. The most common AEs that resulted in changes to treatment were infusion-site reactions, skin rash, and uveitis.
According to the authors, the 4-year follow-up in this analysis offers important insight into treatment with CT-P13, and that “CT-P13 demonstrated encouraging drug retention rates and retention times, as well as reasonable long-term efficacy and safety.”
Reference
Kim HA, Lee E, Lee SK, et al. Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology biologics registry [published online July 19, 2019]. Clin Exp Rheumatol. clinexprheumatol.org/article.asp?a=13765.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.